Last $37.61 USD
Change Today -0.90 / -2.34%
Volume 327.1K
CNMD On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

conmed corp (CNMD) Key Developments

CONMED Corporation Announces Quarterly Cash Dividend Payable on October 6, 2014

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on October 6, 2014 to all shareholders of record as of September 15, 2014.

CONMED Corporation Reports Earnings Results for the Six Months Ended June 30, 2014

CONMED Corporation reported earnings results for the six months ended June 30, 2014. For the six months, the company reported net income of $18.88 million, or $0.68 per diluted share, compared to $20.02 million, or $0.71 per diluted share, for the same period ended June 30, 2013. Net sales were $370.09 million, compared to $380.01 million for the same period ended June 30, 2013.

CONMED Corporation Announces Earnings Results for the Second Quarter Ended June 30, 2014; Revises Earnings Guidance for the Full Year 2014

CONMED Corporation announced earnings results for the second quarter ended June 30, 2014. For the quarter, the company reported adjusted diluted earnings per share increased 9.3% to $0.47, compared with $0.43 in the prior-year. Sales were $188.2 million, a decrease of 2.5%, caused principally by weaker sales of general surgery devices, surgical visualization capital products and the discontinuance of the Cascade PRP product line. Diluted earnings per share on a GAAP basis came in at $0.37, an increase of 8.8% over the prior year period. Sales were $188.2 million, a year-over-year decline of 2.5% or 2.3% on a constant currency basis. This was comprised of a 2.3% decrease in single-use devices and the 3.1% decline in capital products compared to the second quarter last year on a reported basis. At the end of the quarter, the net debt-to-book capitalization calculation was 21.1%, an amount that will allow the company to continue to return cash to shareholders in the form of dividends and share repurchases, as well as seeking selective acquisitions. The company cut its earnings guidance for 2014. The company now expects 2014 sales of $735 million to $745 million, compared with its prior guidance of $770 million to $780 million, due to the first half sales results and its outlook for the remainder of the year. It lowered its forecast for adjusted earnings per share to $1.85 to $1.95, down from its prior guidance of $1.90 to $2.00. These reductions in sales and earnings are a result of an environment of lower health care procedure counts in the United States and new product introductions coming later in the year.

CONMED Corporation Announces Management Changes

CONMED Corporation announced that Joseph Corasanti is stepping down as Chief Executive Officer, President and a member of the Board of Directors, effective immediately. The Board has appointed Curt Hartman, an independent director of CONMED and the former Interim CEO and CFO of Stryker Corporation, as Interim Chief Executive Officer. In addition, after nearly 44 years of service to CONMED, founder Eugene Corasanti has decided to retire from the Board and as an employee, effective immediately. The company also announced that Bill Abraham is retiring as Executive Vice President of Business Development, effective as of the conclusion of a transition period (which is expected to be no later than September 30, 2014). The Board also announced that it has appointed Charles Farkas, a Senior Partner at Bain & Company and former North American Head of Bain's Healthcare Practice, as a new independent director, effective immediately. Mr. Farkas has been added to the Audit Committee as well as the search committee to identify candidates for the permanent CEO position and will stand for election during the 2014 Annual Meeting of Shareholders on September 10, 2014.

CONMED Corporation Mulls Acquisitions

CONMED Corporation (NasdaqGS:CNMD) is seeking acquisitions. Rob Shallish, Executive Vice President, Finance and Chief Financial Officer of CONMED said, "At the end of the quarter, the net debt-to-book capitalization calculation was 21.1%, an amount that will allow CONMED to continue to return cash to shareholders in the form of dividends and share repurchases, as well as seeking elective acquisitions."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CNMD:US $37.61 USD -0.90

CNMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ascom Holding AG SFr.13.85 CHF +0.30
Cantel Medical Corp $35.28 USD -1.36
Integra LifeSciences Holdings Corp $49.76 USD -0.73
Masimo Corp $20.99 USD -0.18
NuVasive Inc $36.78 USD -0.40
View Industry Companies
 

Industry Analysis

CNMD

Industry Average

Valuation CNMD Industry Range
Price/Earnings 30.1x
Price/Sales 1.4x
Price/Book 1.7x
Price/Cash Flow 29.6x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CONMED CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.